The brain's immune cells removed plaques and helped restore a healthier environment in the brains of immunized patients. For over 30 years, scientists have focused on treating Alzheimer’s disease by ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...

For decades, scientists have focused on amyloid plaques—abnormal clumps of misfolded proteins that accumulate between neurons ...

At high levels of brain amyloid-beta, women had more aggressive ... when this difference in tau starts to emerge in the disease process. We can see that older women have higher levels of tau ...

Transthyretin (ATTR) amyloidosis is a life-threatening, gain-of-toxic-function disease characterised by extracellular deposition of amyloid fibrils composed of transthyretin (TTR). TTR protein ...

Amyloidosis is the basis of several serious diseases, such as Alzheimer disease and Parkinson disease. This process involves the formation of amyloid fibrils, crystal-like collections of misfolded ...

Lower skeletal muscle mass was associated with an increased risk for short- and long-term mortality in patients with cardiac amyloidosis (CA). This association was particularly strong with ...

Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, Cardiovascular Disease, and Neuroscience, each representing a blockbuster opportunity ...